IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration
Neumora Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on external capital to fund its precision psychiatry pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | -$0.18+8.4% vs -$0.20 | $16,000 vs — |
Q3 2026 Aug 14, 2026 | -$0.23+4.2% vs -$0.24 | — vs — |
Q2 2026 May 7, 2026 | -$0.30+6.3% vs -$0.32 | — vs — |
Q2 2026 Mar 16, 2026 | -$0.35-2.9% vs -$0.34 | — vs — |
IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Benchmark NMRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neumora Therapeutics, Inc. Common Stock (NMRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.37 | $68.46M | -0.36 | — | -1190187.5% | -320.56% | — | |
| $18.67 | $3.2B | 9.04 | 11.87% | 30.13% | 28.03% | — | |
| $18.49 | $1.36B | 6.89 | 18.52% | 43.79% | 15.84% | — | |
| $137.01 | $7.05B | -45.68 | 65.55% | -18.18% | -189.73% | — | |
| $310.27 | $8.65B | -25.19 | -100% | — | -29.41% | — | |
| $60.97 | $5.06B | -48.03 | 114.51% | -9.17% | — | — |
Neumora Therapeutics, Inc. Common Stock (NMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neumora Therapeutics, Inc. Common Stock (NMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jul 27, 2026·SEC
Jun 15, 2026·SEC
Get notified when NMRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neumora Therapeutics, Inc. Common Stock (NMRA) stock FAQ — growth, dividends, profitability & financials explained
Neumora Therapeutics, Inc. Common Stock (NMRA) reported $0.0M in revenue over the trailing twelve months.
No. Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $190.4M over the trailing twelve months.
Neumora Therapeutics, Inc. Common Stock (NMRA) had a return on equity (ROE) of -320.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $167.3M over the trailing twelve months.